CN1985984A - Medicine composition for treating neurosis - Google Patents
Medicine composition for treating neurosis Download PDFInfo
- Publication number
- CN1985984A CN1985984A CNA2006101022554A CN200610102255A CN1985984A CN 1985984 A CN1985984 A CN 1985984A CN A2006101022554 A CNA2006101022554 A CN A2006101022554A CN 200610102255 A CN200610102255 A CN 200610102255A CN 1985984 A CN1985984 A CN 1985984A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- present
- rhizoma
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a kind of neurosis treating medicine composition, which is prepared bupleurum root, kudzu vine root, corydalis tuber, white peony root, cassia twig and other nine kinds of Chinese medicinal materials in certain weight proportion. The medicine composition may be used in preparing different preparations for treating different types of neurosis, and has high curative effect and fast acting. The present invention is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of medicinal preparation, specifically a kind ofly be particularly suitable for treating neurosal pharmaceutical composition.
Technical background
Neurosis is a kind of commonly encountered diseases, a series of spirit, nerve and somatization that it normally causes cerebral activity generation temporary function disturbance to be caused by the interaction of various factorss such as personality, psychology, society, and when clinical examination, all can not check corresponding pathology sign.Neurosal course of disease delay, and sickness rate is ascendant trend year by year.World Health Organization (WHO) calculates that according to various countries' survey data neurosal crowd's sickness rate is about 5%～8%.The sickness rate of western developed country is generally 10%～20%, and neurosis is generally popular in Chinese population, and its sickness rate should be higher than western developed country.The common type of neurosis has clinically: neurasthenia, hysteria, obsession, phobia, anxiety neurosis, depression and hypochondria.
According to Chinese psychiatric disorders classification (CCMD-3) standard, will be that main person is referred to as " cardiovascular neurosis " also with cardiovascular symptom, be that main person is referred to as " gastrointestinal neurosis " with gastrointestinal symptoms.Clinical experience shows, dissimilar neurosiss has common pathogeny and close Clinical symptoms, as depression, fatigue, headache, have a sleepless night, feel dizzy, degradation under hypomnesis, dreaming often and waking easily, muscle and arthralgia, rapid breathing, distractibility, the ability to work.Dissimilar in addition patients has its special clinical manifestation again, is cardiopalmus, precordialgia, sensation of oppression over the chest with shortness of breath as cardiac nerve disease patient outstanding behaviours; Gastric neurosis patient's outstanding behaviours is that breast side of body account is full, nausea and vomiting, belch eructation, belching and acid regurgitation, abdominal distention distending pain etc.; The anxiety neurosis patient shows as nervous anxiety, dysphoria, in a constant state of anxiety etc.; Patients with depression shows as spirit depressing, fatigue and weak, headache and dizzy, body sense of discomfort and sleep disorder etc.At present, neurosal drug treatment can be summarized as two big classes: adopt chemistry (synthetic or extraction) medicine symptomatic treatment and the dialectical treatment of Chinese medicine.The latter controls according to dialectical the executing of the state of an illness, adopts different prescriptions to add and simplifies the sanction treatment.Adopt chemotherapy, the clinicist normally gives antidepressants and anxiolytic drugs, as imipramine, citalopram, and paroxetine, deanxit etc.To painstaking effort cast neurosis, the neurosal treatment of gastrointestinal type, generally also be to give antidepressants or anxiolytic drugs, add beta-blocker, metoclopramide simultaneously more to the ill or promote digestive tract power reinforcing medicine motilium etc.Clinical practice shows that these chemicals performance curative effects are slower, need 10-15 days usually, gets the effect back and also need adhere to the long period of taking medicine, in case and drug withdrawal, the state of an illness also rebound phenomenon can occur.Have the scholar that this is studied, the result shows, has 50% to accept recurrence (seeing " Chinese medical information newspaper " 2003 18 volumes P13 for details) to have occurred after patient's drug withdrawal of anti-depressant therapy.As everyone knows, the untoward reaction of chemicals is comparatively common.In addition, the easy and other medicines generation interaction of most of antidepressants and antianxiety drugs is share as deanxit and oxidase inhibitor, can cause hypertensive crisis; Share with guanethidine, can reduce its drug effect; Seroxat suppresses liver cytochrome P 450 isozyme C YP2D6, and multiple medicine blood concentration by this enzymes metabolism is raise.Bring potential safety hazard and inconvenience like this, promptly can for the patient who is taking other medicines.
The traditional Chinese medical science thinks that neurosis is by due to the internal damage by the excessive seven emotions, promptly crosses excessive joy impairing the heart, crosses sad lung, crosses excessive anger impairing the liver, melancholy impairing the spleen, fear impairing kidney.Therefore, the traditional Chinese medical science with neurosis be classified as cardiopalmus, palpitation with a distress feeling, be insomnia, the category of the thoracic obstruction, dirty dry, stagnation of QI due to depression of the liver.The traditional Chinese medical science once adopted traditional prescription to treat for neurosis, but these prescriptions are mostly just effective to certain a part of particular patient.As the Yueju Wan (Rhizoma Atractylodis, Rhizoma Cyperi, Rhizoma Chuanxiong, Massa Medicata Fermentata, Fructus Gardeniae) of Zhu Danxi mainly to the chest and diaphragm due to gas, blood, food, expectorant, wet, the fire stagnation knot full vexed, diseases such as gastral cavilty goes up painful, indigestion, belching and acid regurgitation are effective; Somatizations such as the upper abdomen distension due to the suitable treatment of the Xiao Jianzhong Tang of Zhang Zhongjing or Huangqi Jianzhong Tang (Ramulus Cinnamomi, Radix Paeoniae, Rhizoma Zingiberis Recens, Fructus Jujubae, Radix Glycyrrhizae, the Radix Astragali etc.) Deficiency and coldness of spleen and stomach etc., abdominal distention, stomachache, eructation; Radix Bupleuri adds that Os Draconis Concha Ostreae soup (Radix Bupleuri, Radix Scutellariae, the Rhizoma Pinelliae, Radix Ginseng, Plumbum preparatium, Os Draconis, Concha Ostreae, Ramulus Cinnamomi, Poria, Fructus Jujubae, Rhizoma Zingiberis Recens, Radix Glycyrrhizae) then mainly improves such as chest pain, uncomfortable in chest, tired, unable, cardiopalmus, breathes hard, has a headache, somatization and autonomic nerve symptom such as dizzy, dizzy, and this side biases toward the treatment anxiety symptom; Herba Sidae Rhombifoliae soup (Radix Bupleuri, Radix Scutellariae, Radix Codonopsis, the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Jujubae, Radix Glycyrrhizae) biases toward the alternate attacks of chills and fever due to the few sun of the evil visitor of treatment, has a dizzy spell, and the costa sternales distension, bitter taste in the mouth and dry throat etc. have better curative effect to autonomic nervous function imbalance and liver and gall system disorders; It is capable stagnant that BANXIA HOUPU TANG (Rhizoma Pinelliae, Cortex Magnoliae Officinalis, Poria, Rhizoma Zingiberis Recens, Folium Perillae) then focuses on dissipating depression of QI, and the gastrointestinal symptom that alleviate depression is caused has curative effect preferably; Banxia xiexin decoction (Rhizoma Pinelliae, Rhizoma Coptidis, Radix Scutellariae, Rhizoma Zingiberis, Radix Codonopsis, Fructus Jujubae, Radix Glycyrrhizae) focuses on removes upper abdomen feeling of fullness, nausea and vomiting, and major function is a relieving the inhibited functional activities of QI, falls Yang Heyin; And Flos Inulae Haematitum soup is used to declare logical upper abdomen feeling of fullness and the moon to fall sun equally; Japan's how bright quick JIAWEI XIAOYAO SAN of happiness (Radix Bupleuri, Rhizoma Atractylodis, Fructus Gardeniae, Cortex Moutan, Herba Menthae, Radix Paeoniae, Radix Angelicae Sinensis, Poria, Rhizoma Zingiberis Recens, Radix Glycyrrhizae) treatment, the emotion symptom is had better curative effect, and this side biases toward emotion symptoms such as treatment irritability, sensitivity, anxiety, indignation; The WEIDANTANG of Sun Simiao (Rhizoma Pinelliae, Caulis Bambusae In Taenia, Fructus Aurantii Immaturus, Pericarpium Citri tangerinae, Poria, Radix Glycyrrhizae) then biases toward regulating the stomach and sending down the abnormal ascending QI, clearing away phlegm is exempted from drink, function of gallbladder promoting relieving restlessness, to regulating cerebral nerve and free function of nervous system, alleviate coronary spasm, decreased heart rate and myocardial oxygen consumption have curative effect preferably.At present, it is according to the dialectical principle of controlling of executing that most of clinically Chinese physician treats neurosis, the prescription sanction is treated, i.e. " Shi Qifa and not its side of mud ".As to the milk-livered person of stagnation of liver-QI, be main formula generally with Radix Bupleuri, BAIYAO, Fructus Aurantii, Rhizoma Chuanxiong, Rhizoma Cyperi, Huai wheat, Radix Glycyrrhizae, Fructus Jujubae, then with disease plus-minus,, add Caulis Polygoni Multiflori, Flos Albiziae etc. as cardiopalmus dormancy person less; Uneasy in either sitting or lying, emotionally upset person add Bulbus Lilii, the Rhizoma Anemarrhenae etc.; Chest pain person adds Rhizoma Corydalis, Rhizoma Chuanxiong etc.; To the deficiency of both the heart and spleen person, be main formula generally with the Radix Astragali, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Poria, Radix Polygalae, Semen Ziziphi Spinosae, with the disease plus-minus,, add Radix Rehmanniae Preparata, the Radix Paeoniae Alba, Colla Corii Asini then as the simple and unadorned person of dizzy cardiopalmus, anemia and pallor; The heavier person that has a sleepless night adds Fructus Schisandrae Chinensis, Semen Platycladi; The person of being off one's feed adds Fructus Crataegi (parched to brown), Pericarpium Citri Reticulatae etc.Though above-mentioned Chinese medicinal formulae and the dialectical rule of controlling of executing have certain curative effect to neurosis, and be very high to doctor's diagnosis and treatment specification requirement, and medicine is not easy to suitability for industrialized production and uses, and this has increased patient's diagnosis and treatment cost undoubtedly greatly.Moreover the symptom that neurosis showed is numerous and diverse, and also there is the phenomenon of mutual intersection, infiltration, transfer, coexistence in many clinical symptoms.Therefore, subject range is narrower, and the single Chinese medicinal formulae of effect can not satisfy the needs of clinical practice far away.The person can develop at the neurosis pathogenesis to press for the medical research at present, and many target spots are controlled neurosal symptom, can suitability for industrialized production, reduce the diagnosis and treatment cost, and the medicine that neurosis is effectively treated.
Summary of the invention
Purpose of the present invention just provides a kind of polytype neurosis and good effect, rapid-action and can be suitable for the pharmaceutical composition that suitability for industrialized production is used of being applicable to.
The object of the present invention is achieved like this:
The tradition traditional Chinese medical science is thought " the heart being a vital viscus like a king of the body, here gods go out ".Neurosal all symptoms are all relevant with " gods ".The inventor is summarised as stagnation of QI due to depression of the liver, depression of liver-QI, coagulation of QI-blood, obstruction mechanism of qi according to clinical practice for many years with neurosal main pathogenesis.Depression of liver-QI then causes coagulation of QI-blood, and the then clear sun of coagulation of QI-blood can not rise, and turbid yin can not descend; Sun can not rise and when body is in clearly, turbid yin can not descend, on disturb gods, when blocking the state of upper, middle and lower three warmers mechanism of qi, can cause cardiopalmus, uncomfortable in chest, feel suffocated, chest pain, dyspnea, have a headache, have a dizzy spell, a series of clinical syndromes such as anxious, insomnia and dreamful sleep, tinnitus dim eyesight, nausea and vomiting, abdominal distention abdominal distention, acid regurgitation eructating foul odor, belch eructation.So prescription of the present invention design is to be monarch drug with Radix Bupleuri, it serve as basic stagnating with mediation mechanism of qi, strongly fragrantization of row, and assistant with YIN and YANG balance regulating, conciliate the medicine of Ying Wei, a surname's venting QI-blood, tranquilizing the mind, make every effort to reach the purpose for the treatment of neurosis from overall pathogenesis.
Pharmaceutical composition of the present invention is named as " Radix Bupleuri feel at ease preparation " in clinical practice.
Pharmaceutical composition of the present invention includes the Chinese medicinal components of following weight fraction ratio:
10 parts of Radix Bupleuri--100 parts, 1 part of Radix Puerariae--50 parts, 1 part of Rhizoma Corydalis--30 parts, 1 part of Radix Paeoniae--30 parts, 1 part of Ramulus Cinnamomi--30 parts, 0 part of Spica Prunellae--30 parts, 0 part of Concha Margaritifera--100 parts, 0 part of Os Draconis--100 parts, 0 part of Concha Ostreae--100 parts, 0 part of the Rhizoma Pinelliae--30 parts, 0 part in Poria--100 parts, 0 part in Rhizoma Zingiberis Recens--30 parts, 0 part in Fructus Jujubae--30 parts, 0 part in Radix Glycyrrhizae--30 parts.
One of preferred version of pharmaceutical composition of the present invention is: described pharmaceutical composition includes the Chinese medicinal components of following weight fraction ratio:
30 parts of Radix Bupleuri--100 parts, 25 parts of Radix Puerariaes--50 parts, 15 parts of Rhizoma Corydalis--30 parts, 10 parts of Radix Paeoniaes--20 parts, 10 parts of Ramulus Cinnamomi--20 parts, 5 parts of Spica Prunellaes--20 parts, 20 parts of Concha Margaritiferas--30 parts, 20 parts of Os Draconis--30 parts, 20 parts of Concha Ostreaes--30 parts, 5 parts of the Rhizoma Pinelliaes--15 parts, 20 parts in Poria--80 parts, 5 parts in Rhizoma Zingiberis Recens--15 parts, 5 parts in Fructus Jujubae--15 parts, 5 parts in Radix Glycyrrhizae--15 parts.
Two of the preferred version of pharmaceutical composition of the present invention is: described pharmaceutical composition includes the Chinese medicinal components of following weight fraction ratio:
50 parts of Radix Bupleuri--100 parts, 30 parts of Radix Puerariaes--50 parts, 15 parts of Rhizoma Corydalis--30 parts, 15 parts of Radix Paeoniaes--30 parts, 15 parts of Ramulus Cinnamomi--30 parts, Os Draconis 50--100 part, 30 parts in Poria--100 parts, 20 parts in Radix Glycyrrhizae--30 parts.
Three of the preferred version of pharmaceutical composition of the present invention is: described pharmaceutical composition includes the Chinese medicinal components of following weight fraction ratio:
10 parts of Radix Bupleuri--100 parts, 1 part of Radix Puerariae--50 parts, 1 part of Rhizoma Corydalis--30 parts, 1 part of Radix Paeoniae--30 parts, 1 part of Ramulus Cinnamomi--30 parts, 10 parts of Spica Prunellaes--30 parts, 50 parts of Concha Margaritiferas--100 parts, 5 parts of the Rhizoma Pinelliaes--30 parts, 20 parts in Poria--100 parts, 5 parts in Rhizoma Zingiberis Recens--30 parts, 1 part in Radix Glycyrrhizae--30 parts.
Four of the preferred version of pharmaceutical composition of the present invention is: described pharmaceutical composition includes the Chinese medicinal components of following weight fraction ratio:
10 parts of Radix Bupleuri--100 parts, 10 parts of Radix Puerariaes--50 parts, 10 parts of Rhizoma Corydalis--30 parts, 10 parts of Radix Paeoniaes--30 parts, 10 parts of Ramulus Cinnamomi--30 parts, 20 parts of Spica Prunellaes--30 parts, 10 parts of the Rhizoma Pinelliaes--30 parts, 50 parts of Concha Ostreaes--80 parts, 20 parts in Poria--50 parts, 10 parts in Fructus Jujubae--30 parts, 10 parts in Radix Glycyrrhizae--30 parts.
In above-mentioned prescription:
Radix Bupleuri is the monarch drug in the pharmaceutical composition of the present invention, its property of medicine suffering, hardship, is slightly cold, and goes into liver, gallbladder, percardium.This medicine can be declared logical stagnation of QI due to depression of the liver, yang invigorating QI invigorating, declared smooth QI and blood in prescription of the present invention, eliminating stagnation regulating menstruation, promoting the circulation of QI to relieve pain.It is alleviation feeling of stuffiness in chest hypochondriac pain in the prescription of the present invention, separates the principal agent of alternate attacks of chills and fever, reconciling superficies and interior, benefiting qi and raising yang, ascension qi-blood-body fluid; But this drug component has the consumption of YIN-fluid of bringing out, excessive rising of liver-YANG person's effect, so need the following all medicines of special 5 usefulness.
Radix Puerariae is first ministerial drug in the pharmaceutical composition of the present invention, and its property of medicine suffering, sweet, flat is gone into spleen, stomach warp, has the yang invigorating qi invigorating functions, so assist a ruler in governing a country the Radix Bupleuri benefiting qi and raising yang; Simultaneously, because Radix Puerariae also has the effect of promoting the production of body fluid to quench thirst, expelling pathogenic factors from muscles rash, harmonizing yingfen and weifen, alleviation Entries stiffback pain, breast side of body painful abdominal mass pain, so it also can strengthen the effect that Radix Bupleuri is alleviated feeling of stuffiness in chest hypochondriac pain.
Rhizoma Corydalis is second ministerial drug in the pharmaceutical composition of the present invention, and its property of medicine suffering, hardship, temperature are gone into liver, lung, spleen channel, are gas medicine in the blood.This medicine has the effect that upwards strengthens Radix Bupleuri, Radix Puerariae promoting the circulation of QI to relieve pain in prescription of the present invention, strengthen the curative effect of Radix Paeoniae blood circulation promoting and blood stasis dispelling, easing the affected liver to relieve pain downwards.
Ramulus Cinnamomi is the 3rd ministerial drug in the pharmaceutical composition of the present invention, and its property of medicine suffering, sweet, warm is gone into the heart, lung, urinary bladder channel.This medicine has the effect of warming the meridian for promoting the flow of YANG QI, harmonizing yingfen and weifen, diaphoresis expelling pathogenic factors from muscles, reconciling superficies and interior, flat secret negative and positive, warm venting QI-blood in prescription of the present invention.
Radix Paeoniae (can select the Radix Paeoniae Alba or Radix Paeoniae Rubra for use) is the 4th ministerial drug in the pharmaceutical composition of the present invention, its property of medicine hardship, acid, is slightly cold, and goes into Liver Channel, has the effect that the yin fluid astringing of nourishing blood, easing the affected liver to relieve pain, suppressing the hyperactive liver are contained sun.This medicine is helped mutually with Radix Bupleuri, Radix Puerariae yang invigorating QI invigorating in prescription of the present invention, can further bring into play the effect that suppressing the hyperactive liver is contained sun, the beneficial battalion of yin fluid astringing, relieving spasm to stop pain, Yin Yang balancing lifting.And Ramulus Cinnamomi and Radix Paeoniae are share, and also can further bring into play the effect of its diaphoresis expelling pathogenic factors from muscles, reconciling superficies and interior, YING and WEI regulating.
Spica Prunellae is the adjuvant drug in the pharmaceutical composition of the present invention, and its property of medicine suffering, hardship, cold are gone into liver, gallbladder meridian, reach the head on the other drug component among the bootable the present invention of this medicine, are lowered to four ends, all over walking meridians, clearing away liver-fire, Disperse hepatic depression.This medical instrument has balance Radix Bupleuri, the excessive yang invigorating of Radix Puerariae, and the effect that balance Ramulus Cinnamomi excessively activates yang makes this prescription can steadily be used for the patient of Kidney-Yin loss, outward dispersion of deficient YANG, excessive rising of liver-YANG and Nei Sheng phlegm-fire deficiency-heat, and can remove the fire of the strongly fragrant heat-transformation of a specified duration of internal organs meridians; The hardship of this medicine, the cold abnormal smells from the patient that then can assist Radix Paeoniae balance said medicine, performance yin fluid astringing benefit battalion, suppressing the hyperactive liver are contained the effect of sun.
Os Draconis, Concha Ostreae, Concha Margaritifera are adjuvant drug in pharmaceutical composition of the present invention, have suppressing the hyperactive liver and subsiding YANG, tranquillizing the mind by relieving convulsion, convergence and take off, pacify the effect that soul is decided soul, the heart nourishing and intellengence improving admittedly.Os Draconis, Concha Ostreae, Concha Margaritifera three can select one in pharmaceutical composition of the present invention, also can select its two, or three combination.
The Rhizoma Pinelliae is the adjuvant drug in the pharmaceutical composition of the present invention, available Rhizoma Pinelliae Preparata (Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Rhizoma Pinelliae, Rhizoma Pinelliae Preparatum etc.); Flat stomach sending down the abnormal ascending QI, the clearing away phlegm that this medicine of 5 usefulness can further strengthen pharmaceutical composition of the present invention exempted from the effect of drink, the alleviating distention in middle-JIAO therapeutic method to keep the adverse QI flowing downwards, mind tranquilizing and the heart calming, stomach function regulating preventing or arresting vomiting.
Poria is the adjuvant drug in the pharmaceutical composition of the present invention, this medicine of 5 usefulness can further strengthen spleen invigorating invigorating middle warmer of the present invention, mind tranquilizing and the heart calming, surely throb with fear relieving restlessness, pacify soul and decide the effect that soul, clearing away phlegm are exempted from drink.
Rhizoma Zingiberis Recens, Fructus Jujubae, Radix Glycyrrhizae are the messenger drug in the pharmaceutical composition of the present invention, have coordinating the actions of various ingredients in a prescription and strengthen pharmaceutical composition spleen invigorating of the present invention and in, the effect of stomach function regulating preventing or arresting vomiting.
The medicine of existing inspiration yang-energy, ascension qi-blood-body fluid in the pharmaceutical composition of the present invention has the medicine of restraining cloudy gas, flat secret negative and positive again, and Yin grows while yang is generating is prosperous, the body fluid foot of QI and blood then; The medicine that adds balance whole body ascending or descending movement of vital Qi, the logical whole body the four stages in the course of an epidemic febrile disease of a surname in the pharmaceutical composition of the present invention in addition; Then depression of liver-QI can be opened, and stagnation of QI due to depression of the liver can remove, and coagulation of QI-blood can lead to, and the whole body the four stages in the course of an epidemic febrile disease then can normally follow capable compress; Simultaneously, the medicine that soul is decided the effect of soul, the heart nourishing and intellengence improving is taken off, pacified to assistant admittedly with having suppressing the hyperactive liver and subsiding YANG, tranquillizing the mind by relieving convulsion, convergence in the pharmaceutical composition of the present invention; The purpose of " mechanism of qi unobstructed, calm the nerves and throb with fear surely " so can fundamentally reach.
Pharmaceutical composition of the present invention can be used for treating various types of neurosiss, as anxiety type neurosis, depressive type neurosis, heart neurosis, gastrointestinal neurosis etc.
Pharmaceutical composition of the present invention is formulation method routinely, is prepared into dosage forms such as capsule, tablet, powder, pill, granule, powder, oral liquid.
The usage and dosage of medicine of the present invention is: adult's oral medication, every day 2-3 time, each 500--2000mg.The clinicist also can determine the usage and dosage of medicine according to patient's concrete condition.
Pharmaceutical composition of the present invention all has excellent curative to various types of neurosiss, untoward reaction seldom, defecation frequency increased when only a few patient increased at dosage, then disappeared after the decrement or along with continuing medication.The neurosis patient treatment take a turn for the better or the recovery from illness drug withdrawal after the disease relapse rate low, it is very little to take side effect for a long time.
The beneficial effect of pharmaceutical composition of the present invention has obtained checking by following experiment.
Statistical processing and analysis (SPAN) in an embodiment: measurement data is selected the t check for use, and enumeration data is selected X for use
2Check or direct probability computing method, the SPSS10.0 computed in software is adopted in all statistical computations, is that difference has statistical significance with P＜0.05.
The specific embodiment is as follows:
Embodiment 1: medicine antagonism reserpine induced mice blepharoptosis of the present invention experiment
Experimental technique
Pharmacology teaching and research room of preclinical medicine institute of Hebei Medical University uses 40 of Kunming mouses, and male and female half and half are divided into the blank group at random, positive drug matched group, experimental group 1 and experimental group 2, totally 4 groups.More than each group all irritate stomach and give volume 0.2ml/10g the liquid of body weight, the blank group is only fed water; Positive drug control group lumbar injection imipramine 25mg/kg, experimental group gives medicated powder of the present invention, irritates stomach (being divided into experimental group 1, experimental group 2 thus), medication 7 days according to 1.0g/kg, 2.0g/kg respectively; In the last administration preceding 1 hour, observe earlier and have or not blepharoptosis, subcutaneous injection of reserpine 0.5mg/kg immediately surveys mice blepharoptosis degree after 5 hours then.
In the experiment, mice blepharoptosis degree is directly proportional with the depressed degree of mice, and the blepharoptosis score value is higher, represents its depressed degree more serious; The antidepressant effect of the lower expression medicine of blepharoptosis scoring is stronger.
The blepharoptosis standards of grading: it is 0 minute that eye is opened entirely, and 1/4 closes one's eyes is 1 minute, and 1/2 closes one's eyes is 2 minutes, and 3/4 closes one's eyes is 3 minutes, and the full cut-off eye is 4 minutes;
Experimental result sees table 1 for details.
Table 1:
| Group | The example number | The blepharoptosis scoring |
| The blank group | 10 | 3.50±0.71 |
| Positive controls | 10 | 1.8±1.03* |
| Experimental group 1 | 10 | 2.40±0.52* |
| Experimental group 2 | 10 | 2.10±0.74* |
* P＜0.05, positive controls, experimental group 1, experimental group 2 and blank group are relatively.
Experimental result shows, positive controls, experimental group 1, experimental group 2 compare with the blank group that there were significant differences (P＜0.05), show that both all have significant antidepressant effect; And experimental group 1, experimental group 2 are compared no difference of science of statistics (P＞0.05) with positive controls, show that the effect of blepharoptosis effect of the anti-reserpine induced mice of medicine of the present invention and imipramine is suitable, and antidepressant effect is similar between the two.
Embodiment 2: medicine of the present invention is to prolonging the influence of the length of one's sleep of pentobarbital sodium inducing mouse
Experimental technique
50 of Kunming mouses, male and female half and half are divided into blank group, positive controls, experimental group at random, totally 5 groups.More than each group all irritate stomach and give volume 0.2ml/10g the liquid of body weight, the blank group is only fed water, positive controls lumbar injection medicine imipramine 25mg/kg, experimental group gives medicated powder of the present invention, irritates stomach (being divided into 3 three groups of experimental grouies 1, experimental group 2, experimental group thus) totally 3 days according to 0.5g/kg, 1.0g/kg, 2.0g/kg respectively; After the last administration 30 minutes, pentobarbital sodium 50mg/kg lumbar injection served as the sleep index with the righting response disappearance, observed the prolong mice pentobarbital sodium inductive length of one's sleep effect of (in minute) of each group.According to prolonging pentobarbital sodium inducing mouse length of one's sleep, can reflect the power of medicine sedative-hypnotic property.Experimental result sees table 2 for details.
Table 2:
| Group | The example number | Prolong the induced hypnotic time (branch) |
| The blank group | 10 | 15.0±7.8 |
| Positive controls | 10 | 28.0±9.4* |
| Experimental group 1 | 10 | 25.5±14.5* |
| Experimental group 2 | 10 | 37.2±17.9* |
| Experimental group 3 | 10 | 41.8±13.3*# |
* P＜0.05, positive controls, experimental group 1,2,3 are compared with the blank group; #P＜0.01, experimental group 3 is compared with positive controls.
Experimental result shows, the effect that prolongs pentobarbital sodium inducing mouse length of one's sleep during medicine low dosage of the present invention is similar to the imipramine effect, then obviously is better than imipramine during higher dosage.Experiment shows that medicine of the present invention has the effect that sleep is slept peacefully, deepens and prolonged to good sedative.
Embodiment 3: the acute toxicological experiment of medicine of the present invention.
Experimental technique
Get 20 of Kunming mouses, body weight 18-22g,, male and female half and half are got medicated powder 30g of the present invention, add water to 75mL, grind and are mixed with 40% suspension, press the 0.4ml/10g body weight and irritate stomach, and administration is 3 times altogether, and administration time is spaced apart 2 hours.For the first time after the administration mice look for food, drink water, movable normal; For the second time mice closes order and squats and crouch after the administration, and to the irritant reaction reduction, after the administration 1.5 hours, 9/20 loose stool occurred.Lethargy appears in mice after the administration for the third time, and after the administration about 1 hour, whole passage of loose stools.Activity of second day whole mice and behavior recover normal after the administration.Observed altogether 7 days, and do not see dead the generation.Male mice body weight 21.4 ± 1.1g before the experiment, experiment finishes back 24.8 ± 1.4g; Female mice body weight 20.5 ± 1.4g before the experiment, experiment is 23.9 ± 1.4g after finishing.
Acute toxicology studies show that, gives the medicine of the present invention (48g/kg) that mice is equivalent to 960 times of amounts of people's clinical practice dosage, and lethargy only appears in mice, and passage of loose stools recovered normal in second day fully.Observed 7, and do not see dead the generation.Simultaneously, the mice body weight is increase trend.Acute toxicity testing shows, safety of medicine of the present invention, avirulence.
Embodiment 4: the clinical adverse monitoring of medicine of the present invention
Select to observe case 200 examples, give, promptly take for each person every day 3 times, each 2 grams, 4 weeks of Time of Administration, tracking and monitoring 6 months than the strong dose amount.
Monitoring result shows that the patient sleeps and deepen and prolongation night, and daytime, brains was pure and fresh, and whole body is strong, and energy and antisecosis are good; All patients all do not have thing common side reaction in degradation sedative hypnotics under unable, tired, dizzy, the exquisite operating accuracy of appearance.
Embodiment 5: medicine of the present invention is for the observation of curative effect that compares before and after the cardiovascular neurosis patient self
The case choice criteria:
Selected patient meets the diagnostic criteria of doctor trained in Western medicine cardiovascular neurosis, the patient of the cardiovascular neurosis of the traditional Chinese medical science (strongly fragrant disease) diagnostic criteria.
The Western medicine diagnose standard:
All have following symptom, and fail to confirm have organic heart disease or other organic disease persons can be diagnosed as cardiovascular neurosis through systems inspection.
1. cardiopalmus: conscious heartbeat is strong or feel nervous, and tachycardia or premature beat can be arranged, and the normal non-burst of cardiopalmus is prominent to be ended, and nervous fatigue often makes it increase the weight of.
2. precordial pain or uncomfortable in chest: the position is often fixing, can be twinge, suppress pain, dull pain or radiating pain, and the outbreak several seconds, outbreak was irrelevant with the labour, how to show effect when rest to a few hours, and containing nitroglycerin is invalid.
3. dyspnea: often feel hypopnea, usually dark air-breathing or sigh incessantly, the Hyperventilation syndrome takes place sometimes.
4. fatigue and weak: the normal sense of patient is excessively tired, myasthenia of limbs, and work and viability significantly descend.
5. autonomic nervous dysfunction symptom: hyperhidrosis, the cold or hotness of brothers, brothers tremble, defecation often, alternate attacks of chills and fever etc.
6. central nervous system's performance: dizziness, headache, insomnia, dreaminess, inappetence etc.
The tcm diagnosis standard: all possess following three above primary symptoms or two primary symptoms add auxilliary disease person more than two:
Primary symptom: the cardiopalmus of showing effect repeatedly, uncomfortable in chest or chest and hypochondrium, pain character are twinge, jumping pain, distending pain, and outbreak continues several minutes or a few hours, and outbreak repeatedly is irrelevant with the labour.
Auxilliary disease: except that primary symptom, with: A breathes hard, contrary QI ascending to the throat; B sighs, belch; The C dizziness, dreaminess.
Auxiliary examination: get rid of organic heart disease through electrocardiogram, ultrasoundcardiogram, X line rabat, exercise stress test etc. inspections, as coronary heart disease and myocardial ischemia, heart failure, myocarditis and cardiomyopathy etc.
The clinical efficacy evaluation criteria:
Clinical recovery: symptom complete obiteration; Produce effects: two grades of symptom decline; Effectively: a descend grade or have clear improvement of symptom; Invalid; Clinical symptoms does not have obvious improvement even increases the weight of.
Man-rate standard: 1 grade: safety, there is not any untoward reaction; 2 grades: compare safety,, do not need special handling, can continue medication if any untoward reaction; 3 grades: safety problem is arranged, moderate untoward reaction is arranged, can continue medication after the processing.4 grades: because of the untoward reaction termination test.
Tcm symptom scalar quantization standard (work out with reference to new Chinese medicine treatment hypertension, angina pectoris, heart failure standard, see Table 3)
Table 3:
| Symptom | Gently | In (adding 1 fen) | Heavy (adding 2 fens) |
| Cardiopalmus (2) | Sense of discomfort takes place once in a while, slight | Happen occasionally, the persistent period is longer, and sense of discomfort is more obvious | Often take place, fear and move, being difficult to tranquilly influences work and lives |
| Chest and hypochondrium (2) | Breast is coerced indistinct vexed pain, twinge (light, as not influence work) | End when doing when breast is coerced vexed pain, twinge, the time see sighs (weight can be stood) | Feeling of oppression and pain in the chest is obvious, and is uncomfortable in chest as suffocating, sigh more than (heavy, as to be difficult to stand) |
| Breathe hard (2) | The sense of breathing hard is light, can stand | The sense of breathing hard is heavy, and the normal sample of doing to sigh is breathed | Breathe hard heavily, deeply breathe and the sample of sighing is breathed constantly, sensation of asphyxia is arranged |
| Be insomnia (2) | Sleep is awakened often or is slept and unstable, and it is too early to wake up morning, but does not influence work | Do not have enough sleep 4 hours, but still can adhere to work | Lie awake all night, be difficult to adhere to work |
| Anxious (2) | Slight uneasy | In a disturbed state of mind | Feel restless |
| Fatigue and weak (1) | Lassitude, energy is poor, still can adhere to routine work and activity | Spirit is tired, and general weakness is adhered to daily routines reluctantly | Energy is seriously tired, is difficult to adhere to daily routines |
| Headache and dizzy (1) | End when doing when slight headache is dizzy | Dizzy pain can be stood, and continues more than | Dizzy pain unbearably, upper punch volume top |
| Alternate attacks of chills and fever (1) | |||
| Aching pain in waist and back (1) | |||
| Brothers tremble (1) |
Case is included standard in: meet auxilliary disease persons such as primary symptoms such as uncomfortable in chest, hypochondriac pain, cardiopalmus, insomnia and fatigue and weak, distending pain in the head, age 18-65 year, male or female.
The case exclusion standard:
Though 1. chest pain, uncomfortable in chest is arranged, through inspections such as electrocardiogram, the exercise test person that turns out to be the angina pectoris;
Though 2. dizziness, feeling of fullness in the head, insomnia are arranged, confirm to suffer from hypertension or vertebral-basilar artery or chronic insufficient cerebral blood supply person on inspection;
3. through system's nerve and psychiatric system inspection, doubting is organic nerve, mental sickness person;
4. merge severe hypertension, severe pulmonary insufficiency, severe arrhythmia, serious primary disease person such as liver, kidney, hemopoietic system;
5. gestation or women breast-feeding their children;
6. allergic constitution or to multiple drug allergy person.
Curative effect is seen and is looked into index:
1. clinical symptoms: uncomfortable in chest, hypochondriac pain, breathe hard, fatigue and weak, dizziness, headache, insomnia etc.
2. clinical sign: blood pressure, heart rate.
3. clinical examination: comprise hemocyte inspection, biochemical analysis, electrocardiogram observation (all cases), thyroid function inspection (as doubting and hyperthyroidism or hypothyroidism inspection).
4. safety assessment project: hematuria is routine examination just; Biochemical hepatic and renal function inspection.
Test method
Clinical data: heart neurosis patient 60 examples, male 19 examples, women 41 examples; Age 18-65 year, outpatient service 48 examples, 12 examples of being in hospital.
Medication: oral for each person every day three medicament capsules of the present invention, each 2.All observe 4 weeks of treatment.
Experimental result: curative effect sees Table 4.
Table 4:
| Follow up a case by regular visits to week | Follow up a case by regular visits to routine number | Clinical cure | Produce effects | Effectively | Invalid | Effective percentage |
| 1 2 3 4 | 60 60 60 60 | 15 40 45 46 | 26 19 14 13 | 19 1 1 1 | 0 0 0 0 | 100％ 100％ 100％ 100％ |
Safety assessment: observe through the treatment of 4 weeks is omnidistance, 60 routine patients adopt Drug therapy bleeding from anus cytoscopy of the present invention, biochemical analysis, electrocardiogram to observe and have no significant change, and have no adverse reaction, and safety belongs to 1 grade.
Result of the test shows, the onset rapidly in 1 week of the curative effect of medicine of the present invention, in 1 week effectively and the ratio of produce effects just reach 100%, the ratio of healing and produce effects reaches 68%.At present, one of all anxiolytic drugs and main deficiency of antidepressant drug are that onset is slow, about 10-15 talent performance curative effect; And medicine outstanding feature of the present invention is rapid-action, and evident in efficacy to neurosal somatization, and untoward reaction is few.
Embodiment 6: the curative effect contrast observing of medicine of the present invention and deanxit treatment cardiovascular neurosis
Clinical diagnosis standard, case selection and exclusion standard, tcm symptom scalar quantization standard, clinical efficacy evaluation criteria are all identical with embodiment 5.Because it is very fast that two medicines are all brought into play curative effect, all can onset in 1 week, so 2 weeks of observation of curative effect.
Clinical data: heart neurosis patient 62 examples, male 22 examples, women 40 examples; Age 19-65 year.The patient is divided into drug test group of the present invention and each 31 example of positive drug (deanxit) matched group at random.Deanxit is that Denmark Ling Bei pharmaceutical factory produces, every contains excitatory neuron blocker depixol 0.5mg, tricyclic antidepressants melitracen 10mg, the mutual antagonism of two medicines, and action compensating, onset is rapid, has become the standard drug and the conventional treatments of countries in the world treatment psychosomatic disease, anxiety and depressive neurosis.See: Lin Xiaohong translates. deanxit---the new drug of treatment neurasthenia and similar symptom. and Shenzhen medical science 1996; 9 (supplementary issue 3): 109-110.
Medication
Oral medicament capsule day of the present invention of test group three times, each 2.Oral deanxit noon morning of matched group each 1 time, each 1.
Result of the test sees Table 5.
Table 5:
| Follow up a case by regular visits to week | Follow up a case by regular visits to routine number | Clinical cure | Produce effects | Effectively | Invalid | Effective percentage |
| The 1st all the 2nd all the 1st all the 2nd weeks of matched group of matched group of test group of test group | 31 31 31 31 | 8 11 0 7 | 13 14 11 13 | 10 6 7 11 | 0 0 13 0 | 100％ 100％ 58.1 100％ |
The 1st all total effective rates relatively all total effective rates in P＜0.05, the second compare P＞0.05
Experimental result shows that medicine of the present invention total effective rate in the 1st week obviously is better than deanxit, and the ratio of clinical cure and produce effects is also apparently higher than deanxit; And the 2nd when week total effective rate and deanxit therapeutic equivalence.Therefore, can prove further that drug effect of the present invention is fast, determined curative effect is the active drug of treatment cardiovascular neurosis.
Embodiment 7: medicine of the present invention is for anxiety neurosis patient's observation of curative effect
The case choice criteria:
There are symptoms such as dysphoria, nervous anxiety, uncomfortable in chest, insomnia, forgetful, fatigue and weak, distending pain in the head in the main suit, and meets anxiety neurosis person through HAS.Age 18-65 year, male or female.
The case exclusion standard:
Through system's nerve and psychiatric system inspection, doubting is organic nerve, mental sickness person; 6. gestation or women breast-feeding their children; Allergic constitution or to multiple drug allergy person.
Hamilton anxiety scale (HAMA) scoring criterion:＞14 are divided into sure anxiety, and＞7 are divided into and have anxiety, do not have anxiety in＜6 minutes.
Curative effect determinate standard: produce effects: the scoring score value reduces 〉=70%; Effectively the scoring score value reduces 〉=50%; Invalid scoring score value reduces＜50%, constant or increase.
Select anxiety neurosis patient totally 62 examples, male's 21 examples, women's 41 examples are divided into two groups at random, each 31 example, 2 weeks of observation of curative effect.
Medication
Test group oral medicine of the present invention every day 3 times, each 2.Each 1 of oral deanxit noon morning of matched group.
Result of the test: curative effect sees Table 6,7,8.
Table 6. anxiety mark
| Baseline values | During the 1st week | During the 2nd week | |
| Test group matched group difference 95% credibility interval P value | 20.13±2.89 20.10±3.14 0.96 | 6.68±4.09 10.32±6.01 -3.64 -6.25，-1.03 0.014 | 5.58±2.72 7.06±4.37 -1.48 -3.33，0.36 0.45 |
The effect of table 7. the 1st week treatment anxiety
| Invalid n (%) | Effective n (%) | Produce effects n (%) | |
| The test group matched group | 5(16.1％) 13(41.9％) | 5(16.1％) 7(22.6％) | 21(67.7％) 11(35.5％) |
P＜0.01
The effect of table 8. the 2nd week treatment anxiety
| Invalid n (%) | Effective n (%) | Produce effects n (%) | |
| The test group matched group | 3(9.7％) 4(12.9％) | 3(9.7％) 7(22.6％) | 25(80.6％) 20(64.5％) |
P＝0.32
Result of the test shows that Drug therapy anxiety neurosis of the present invention is compared with deanxit, the 1st all curative effect performances very fast (P＜0.01), and there were significant differences for both curative effects; The 2nd week, both did not then have significant difference (P=0.32).
Embodiment 8: medicine of the present invention is at the neurosal clinical observation on the therapeutic effect of gastrointestinal
The case choice criteria:
1, meets the CCMD-3 criteria for neurosis;
2, the patient serves as main examining with gastrointestinal disease symptom (as costa sternales distension, belching and acid regurgitation, eructation belch, sigh repeatedly, hepatalgia, the singultus etc. of having the hiccups), but does not have any organic change through the gastrointestinal routine examination.
3, meet anxiety or depressed shower through Han Midun anxiety amount and depression scale scoring.
4, the course of disease is more than 3 months.
Clinical data:
Case load 60 examples, wherein male 21 examples, women 39 examples, 20～68 years old age, the course of disease 3～5 months.All case is divided into medication therapy groups of the present invention (test group) and positive drug matched group (deanxit) at random.32 examples are organized in treatment, wherein male 10 examples, women 22 examples, year mean age (45.12 ± 4.83); Wherein male 11 examples of matched group 28 examples, women 17 examples, mean age (44.16 ± 5.18).Two groups of not statistically significants (P＞0.05) aspect sex, age, the state of an illness, the course of disease.
Test method:
Test group is taken the capsule that medicament composing prescription of the present invention is prepared into, every day three times, each 3.Matched group is taken the deanxit sheet, every day 2 times, each 1.Take and be for 4 weeks the course of treatment.Tracking was followed up a case by regular visits to 6 months.
Efficacy assessment standard: according to Han Midun anxiety amount and depression scale scoring, reducing before wherein integration is treated is produce effects more than 70%; The integration preceding minimizing 50%～70% of treatment is effective; Integration reduce less than 50% before the treatment or increase to invalid.Effectively the patient occurs clinical condition person again for recurring, in total effectively number relapse rate after 6 months.
Clinical efficacy sees Table 9.
Table 9:
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate | Relapse rate (%) |
| The treatment group | 32 | 22 | 10 | 0 | 100 | 9.4 |
| Matched group | 28 | 19 | 9 | 0 | 100 | 15 |
Two groups of total effective rates compare P＞0.05;
Result of the test shows that it is suitable with deanxit that medicine of the present invention is used for the neurosal curative effect of gastrointestinal.
Embodiment 9: medicine of the present invention is used for the treatment of the clinical observation on the therapeutic effect of depressive neurosis
Case is selected:
Diagnosis meets the formulation standard of depressive neurosis in " Chinese mental disorder classification and diagnostic criteria CCMD-3 ", meets HAMD (HAMD) simultaneously and detects total points greater than 20 fens persons.
Select wherein male 22 examples of case 60 examples, women 38 examples, age 22--58 year, course of disease 1-2.
Experimental technique
Case is divided into two groups of test group and matched groups at random.Test group is taken medicament capsule of the present invention, every day 3 times, each 3; The oral deanxit of matched group every day 2 times, early each 1 of noon, be for 4 weeks the course of treatment.
Criterion of therapeutical effect
Produce effects: clinical symptoms is alleviated substantially, and fluctuation is arranged between emotion; The scoring of HAMD scale descends 〉=70%.
Take a turn for the better: clinical symptoms is improved, and emotion has fluctuation; HAMD scale scoring 〉=50%.
Invalid: symptom does not have improvement, emotional instability; HAMD scale scoring≤50%.
Result of the test: curative effect sees Table 10
Table 10
| Group | The example number | Produce effects | Take a turn for the better | Invalid | Total effective rate |
| Test group | 30 | 15 | 12 | 3 | 90 |
| Matched group | 30 | 18 | 10 | 2 | 93 |
Two groups are compared P＞0.05
It is similar to deanxit that medicine of the present invention is used for the curative effect of depressive neurosis.
Following examples have exemplified several dosage forms of medicine of the present invention:
Embodiment 10: the extractum of medicine of the present invention
A, take by weighing Radix Bupleuri 100kg, Radix Puerariae 5kg, Rhizoma Corydalis 15kg part, Radix Paeoniae 1kg, Ramulus Cinnamomi 1kg, Spica Prunellae 15kg, Concha Margaritifera 20kg, Os Draconis 20kg, Concha Ostreae 10kg, Rhizoma Pinelliae Preparatum 5kg, Poria 1kg, Rhizoma Zingiberis Recens 1kg, Fructus Jujubae 10kg, Radix Glycyrrhizae 30kg.Standby.
B, above-mentioned medicine is decocted with water twice, each amount of water was not advisable to have powder, merged decocting liquid twice, filter to get filtrate 1, be condensed into proportion and be 1.30 extractum, add 90--95% ethanol and carry out precipitate with ethanol, reclaim ethanol and concentrated, dry under 45-50 ℃, make dry extract;
Embodiment 11: medicinal granule of the present invention
Dry extract is broken into powder, adds ethanol and make adhesive, add starch and make filler, be pressed into granule.
Embodiment 12: medicine oral liquid of the present invention:
The extractum of pharmaceutical composition of the present invention is dissolved in the 1000ml water, makes the aqueous solution of 2.5% concentration, heating for dissolving, mix homogeneously in the 20ml medicine bottle of packing into, seals, sterilizes.
Embodiment 13: medicinal tablet of the present invention:
The extractum of pharmaceutical composition of the present invention is got 2000 kilograms, and method for preparing tablet thereof adds starch routinely, and dextrin, magnesium stearate etc. are mixed and made into wet grain, and the machine punching press is in blocks, and every contains medicine dry extract 200mg of the present invention.
Pharmaceutical dosage form of the present invention is not limited solely to this, and it can be prepared into more dosage form, as drop pill, capsule, soft capsule, sustained-release preparation or the like.
The preparation method of embodiment 14-19 all is to adopt conventional preparation method, and is just different on drug component and consumption proportion thereof, but all has effect of the present invention.
Above EXPERIMENTAL EXAMPLE, example of formulations can illustrate in greater detail the present invention, but do not limit the present invention in any form.
Claims (5)
1, a kind ofly be used for the treatment of neurosal pharmaceutical composition, it is characterized in that it includes the Chinese medicinal components of following weight fraction ratio:
10 parts of Radix Bupleuri--100 parts, 1 part of Radix Puerariae--50 parts, 1 part of Rhizoma Corydalis--30 parts, 1 part of Radix Paeoniae--30 parts, 1 part of Ramulus Cinnamomi--30 parts, 0 part of Spica Prunellae--30 parts, 0 part of Concha Margaritifera--100 parts, 0 part of Os Draconis--100 parts, 0 part of Concha Ostreae--100 parts, 0 part of the Rhizoma Pinelliae--30 parts, 0 part in Poria--100 parts, 0 part in Rhizoma Zingiberis Recens--30 parts, 0 part in Fructus Jujubae--30 parts, 0 part in Radix Glycyrrhizae--30 parts.
2, pharmaceutical composition according to claim 1 is characterized in that it includes the Chinese medicinal components of following weight fraction ratio:
30 parts of Radix Bupleuri--100 parts, 25 parts of Radix Puerariaes--50 parts, 15 parts of Rhizoma Corydalis--30 parts, 10 parts of Radix Paeoniaes--20 parts, 10 parts of Ramulus Cinnamomi--20 parts, 5 parts of Spica Prunellaes--20 parts, 20 parts of Concha Margaritiferas--30 parts, 20 parts of Os Draconis--30 parts, 20 parts of Concha Ostreaes--30 parts, 5 parts of the Rhizoma Pinelliaes--15 parts, 20 parts in Poria--80 parts, 5 parts in Rhizoma Zingiberis Recens--15 parts, 5 parts in Fructus Jujubae--15 parts, 5 parts in Radix Glycyrrhizae--15 parts.
3, pharmaceutical composition according to claim 1 is characterized in that it includes the Chinese medicinal components of following weight fraction ratio:
50 parts of Radix Bupleuri--100 parts, 30 parts of Radix Puerariaes--50 parts, 15 parts of Rhizoma Corydalis--30 parts, 15 parts of Radix Paeoniaes--30 parts, 15 parts of Ramulus Cinnamomi--30 parts, Os Draconis 50--100 part, 30 parts in Poria--50 parts, 20 parts in Radix Glycyrrhizae--30 parts.
4, pharmaceutical composition according to claim 1 is characterized in that it includes the Chinese medicinal components of following weight fraction ratio:
10 parts of Radix Bupleuri--100 parts, 1 part of Radix Puerariae--50 parts, 1 part of Rhizoma Corydalis--30 parts, 1 part of Radix Paeoniae--30 parts, 1 part of Ramulus Cinnamomi--30 parts, 10 parts of Spica Prunellaes--30 parts, 50 parts of Concha Margaritiferas--100 parts, 5 parts of the Rhizoma Pinelliaes--30 parts, 20 parts in Poria--100 parts, 5 parts in Rhizoma Zingiberis Recens--30 parts, 1 part in Radix Glycyrrhizae--30 parts.
5, pharmaceutical composition according to claim 1 is characterized in that it includes the Chinese medicinal components of following weight fraction ratio:
10 parts of Radix Bupleuri--100 parts, 10 parts of Radix Puerariaes--50 parts, 10 parts of Rhizoma Corydalis--30 parts, 10 parts of Radix Paeoniaes--30 parts, 10 parts of Ramulus Cinnamomi--30 parts, 20 parts of Spica Prunellaes--30 parts, 10 parts of the Rhizoma Pinelliaes--30 parts, 50 parts of Concha Ostreaes--80 parts, Poria part 20--50 part, 10 parts in Fructus Jujubae--30 parts, 10 parts in Radix Glycyrrhizae--30 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101022554A CN100493597C (en) | 2006-12-14 | 2006-12-14 | Medicine composition for treating neurosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101022554A CN100493597C (en) | 2006-12-14 | 2006-12-14 | Medicine composition for treating neurosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1985984A true CN1985984A (en) | 2007-06-27 |
| CN100493597C CN100493597C (en) | 2009-06-03 |
Family
ID=38183013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101022554A Expired - Fee Related CN100493597C (en) | 2006-12-14 | 2006-12-14 | Medicine composition for treating neurosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100493597C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188500A (en) * | 2010-03-19 | 2011-09-21 | 山东省中医药研究院 | Traditional Chinese medicine preparation for treating anxiety neurosis |
| CN102228659A (en) * | 2011-06-28 | 2011-11-02 | 河南省宛西制药股份有限公司 | Chinese medicinal composition for treating generalized anxiety disorder and preparation method thereof |
| CN103550435A (en) * | 2013-11-12 | 2014-02-05 | 周立发 | Traditional Chinese medicine for treating tristimania |
| CN104138592A (en) * | 2014-08-06 | 2014-11-12 | 绍兴市第七人民医院 | Traditional Chinese medicine for universality anxiety disorder curing |
| CN104940697A (en) * | 2015-07-08 | 2015-09-30 | 郭岩海 | Traditional Chinese medicine composite for treating heart-spleen deficiency type heart neurosis |
| CN108096557A (en) * | 2018-01-18 | 2018-06-01 | 刘黎霞 | Treat the Chinese medicine composition of cardiovascular neurosis |
| CN113144106A (en) * | 2021-04-22 | 2021-07-23 | 寇绍杰 | Anxiolytic drug |
| CN116173173A (en) * | 2023-03-24 | 2023-05-30 | 河北医科大学第一医院 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055231A (en) * | 2013-01-22 | 2013-04-24 | 南宁市神明药物研究所有限责任公司 | Method for preparing traditional Chinese medicine preparation |
-
2006
- 2006-12-14 CN CNB2006101022554A patent/CN100493597C/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188500A (en) * | 2010-03-19 | 2011-09-21 | 山东省中医药研究院 | Traditional Chinese medicine preparation for treating anxiety neurosis |
| CN102188500B (en) * | 2010-03-19 | 2012-08-15 | 山东省中医药研究院 | Traditional Chinese medicine preparation for treating anxiety neurosis |
| CN102228659A (en) * | 2011-06-28 | 2011-11-02 | 河南省宛西制药股份有限公司 | Chinese medicinal composition for treating generalized anxiety disorder and preparation method thereof |
| CN102228659B (en) * | 2011-06-28 | 2012-10-31 | 河南省宛西制药股份有限公司 | Chinese medicinal composition for treating generalized anxiety disorder and preparation method thereof |
| CN103550435A (en) * | 2013-11-12 | 2014-02-05 | 周立发 | Traditional Chinese medicine for treating tristimania |
| CN104138592A (en) * | 2014-08-06 | 2014-11-12 | 绍兴市第七人民医院 | Traditional Chinese medicine for universality anxiety disorder curing |
| CN104940697A (en) * | 2015-07-08 | 2015-09-30 | 郭岩海 | Traditional Chinese medicine composite for treating heart-spleen deficiency type heart neurosis |
| CN108096557A (en) * | 2018-01-18 | 2018-06-01 | 刘黎霞 | Treat the Chinese medicine composition of cardiovascular neurosis |
| CN113144106A (en) * | 2021-04-22 | 2021-07-23 | 寇绍杰 | Anxiolytic drug |
| CN116173173A (en) * | 2023-03-24 | 2023-05-30 | 河北医科大学第一医院 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100493597C (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100493597C (en) | Medicine composition for treating neurosis | |
| CN101670076B (en) | Traditional Chinese medicine composition for treating disease of chronic nephritis and preparation method thereof | |
| CN101711850B (en) | Traditional Chinese medicine composition for treating symptoms of myocardial ischemia, palpitation and severe palpitation and preparation method | |
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN102198241B (en) | Medicine for alleviating nervousness and taking care of sub-health | |
| CN101670060A (en) | Traditional Chinese medicine composition for treating such diseases as hepatic stagnation, chest stuffiness and distension and preparation method | |
| CN101703745B (en) | Chinese medicinal composition for treating painful chest and hypochondrium and chest obstruction, and preparation method thereof | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN1320912C (en) | Mind easing oral liquor with gen-seng and lily bulb | |
| CN104983985A (en) | Chinese herba preparation for treating depression | |
| CN103948888A (en) | Traditional Chinese medicinal preparation for treating neurasthenia | |
| CN105999049A (en) | Traditional Chinese medicine composition for treating chronic renal failure and complications thereof | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104383420A (en) | Preparation method of pharmaceutical preparation for treating insomnia and dreaminess | |
| CN101664518B (en) | Moist bath lotion composition, preparation method and application in preparing pharmaceuticals and health products for treating YIN-blood deficiency fatigue syndrome or adiposity | |
| CN103495108B (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN103877376B (en) | A kind of pharmaceutical preparation treating depression | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN102872292B (en) | Traditional Chinese medicine for curing spleen and kidney deficiency type ischemic post-stroke depression | |
| CN105250754B (en) | It is a kind of alleviate menopause symptom Chinese medicine composition and its application | |
| CN1515303A (en) | Chinese medicine preparation for curing coronary heart disease and angina pectoris and its preparation method | |
| CN104352867A (en) | Traditional Chinese medicine composition for treating gestational depression | |
| CN102631618A (en) | Traditional Chinese medicine for treating diabetes | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090603 Termination date: 20141214 |
|
| EXPY | Termination of patent right or utility model |